

Anna Korycka-Wolowiec

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2038794/publications.pdf>

Version: 2024-02-01

10
papers

63
citations

1937632

4
h-index

1872665

6
g-index

10
all docs

10
docs citations

10
times ranked

164
citing authors

#	ARTICLE	IF	CITATIONS
1	The influence of venetoclax, used alone or in combination with cladribine (2-CdA), on CLL cells apoptosis in vitro: Preliminary results. <i>Advances in Clinical and Experimental Medicine</i> , 2022, 31, 0-0.	1.4	0
2	TP53/PLCG2-mutated diffuse large B-cell lymphoma richter transformation (DLBCL-RT) of CLL with unusual CD2 and PD-1 expression. <i>Leukemia and Lymphoma</i> , 2022, 63, 2735-2738.	1.3	0
3	The safety of available chemo-free treatments for mantle cell lymphoma. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1377-1393.	2.4	3
4	Venetoclax in the treatment of chronic lymphocytic leukemia. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 353-366.	3.3	27
5	Bendamustine alone or with rituximab modifies expression of apoptosis-regulating genes and proteins of CLL cells, depending on IGVH mutational status. <i>Leukemia and Lymphoma</i> , 2019, 60, 1409-1419.	1.3	0
6	Ofatumumab for treating chronic lymphocytic leukemia: a safety profile. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1945-1959.	2.4	12
7	Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1371-1391.	3.3	6
8	Cytotoxic and apoptosis-inducing effects of bendamustine used alone and in combination with rituximab on chronic lymphocytic leukemia cells in vitro. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2014, 68, 1433-1443.	0.1	3
9	Clinical Relevance Of VEGF-C/VEGF-D/VEGFR-3 Axis In Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2013, 122, 5060-5060.	1.4	0
10	Pharmacokinetic evaluation and therapeutic activity of bendamustine in B-cell lymphoid malignancies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 1455-1468.	3.3	12